公开(公告)号：US20240382588A1

公开(公告)日：2024-11-21

申请号：US18693109

申请日：2022-09-21

Applicant: MONASH UNIVERSITY

Inventor： Joshua Daniel OOI ,  Peter James EGGENHUIZEN ,  Eric MORAND

IPC: A61K39/00 ,  A61P37/06 ,  C07K14/725 ,  C12N5/0783

Abstract: The present invention relates to methods and compositions for treating autoimmune or inflammatory disease characterised by an aberrant or inappropriate immune response to one or more of Ro60 protein; MPO protein; and Smith protein.

公开(公告)号：US20230270859A1

公开(公告)日：2023-08-31

申请号：US17906601

申请日：2021-03-19

Applicant: MONASH UNIVERSITY

Inventor： Joshua OOI ,  Peter EGGENHUIZEN ,  Eric MORAND

IPC: A61K39/00 ,  C07K14/725 ,  C07K16/28 ,  A61P37/06

CPC classification number: A61K39/4632 ,  C07K14/7051 ,  C07K16/2833 ,  A61K39/4611 ,  A61P37/06 ,  C07K2319/00 ,  A61K2239/13

Abstract: The present invention relates to compositions and methods for the treatment of lupus, particularly systemic lupus erythematosus. The present invention involves, amongst other things, a binding protein comprising a T cell receptor (TCR) α-chain variable (Vα or Valpha) domain and a TCR β-chain variable (Vβ or Vbeta) domain, wherein the binding protein is capable of binding to a complex of a fragment of a Smith protein and an HLA-DR15 or HLA-DR3 molecule.